GILZ和Ki-67在上皮性卵巢癌中的表达及其临床意义研究

目的 探讨GILZ和Ki-67在上皮性卵巢癌中的表达及其临床意义。方法 采用免疫组化SP法对大连医科大学附属第二医院2006-2012年收治的12例正常卵巢组织、19例卵巢良性肿瘤组织及45例上皮性卵巢癌组织标本进行GILZ和Ki-67蛋白表达检测，分析GILZ与Ki-67之间的相关性，并进行相关临床因素分析。结果 （1）GILZ、Ki-67在上皮性卵巢癌中的表达率（57.78%，46.67%）明显高于其在正常卵巢组织和卵巢良性肿瘤组织中的表达率（0，0；0，15.79%）(P<0.05)。（2）GILZ和Ki-67的表达与年龄、组织类型、临床分期、淋巴转移、腹水及化疗疗效均无相关性（P>0.05)。（3）GILZ与Ki-67的表达呈正相关。结论 （1）GILZ和Ki-67在上皮性卵巢癌中的表达明显高于正常卵巢组织和卵巢良性肿瘤组织，提示GILZ和Ki-67在卵巢癌的发生发展中可能扮演重要角色。（2）GILZ表达的增加可导致细胞增殖的增加，其高表达水平可以作为判断卵巢癌恶性程度、病情进展的重要指标。（3）联合检测GILZ和Ki-67对肿瘤的临床诊断、治疗及预后会有一定参考价值。

Expression of GILZ and Ki-67 in epithelial ovarian carcinoma and its clinical implication.

Abstract： Objective To determine the expression and significance of GILZ and Ki-67 in epithelial ovarian cancer. Methods The expression of GILZ and Ki-67 protein was assayed by means of SP immunohistochemical staining in 45 cases of epithelial ovarian cancer, 19 cases of benign ovarian cystoadenoma and 12 cases of normal ovarian tissue. The relativity between GILZ and Ki-67 was analyzed and relevant clinical factors were also analyzed.Results （1）The expression rate of GILZ and Ki-67 in 45 cases of epithelial ovarian cancer was 57.78％and 46.67％, significantly higher than that in 19 cases of benign ovarian cystoadenoma(15.79％ and 0) and 12 cases of normal ovarian tissue(0and 0); (2)The expression of GILZ and Ki-67 were not related to patients’ age, histologic subtypes, clinical stage, lymph node transfer, ascites and response to chemotherapy(P>0.05). (3)There was a positive correlation between GILZ and Ki-67.Conclusions (1)GILZ and Ki-67 expression in ovarian cancer is higher, suggesting that GILZ and Ki-67 play an important role in development and incidence of ovarian cancer.（2）The relationship between GILZ and Ki-67 suggests that GILZ may promote the tumor through high-regulating cell proliferation,whose high expression level can be used as a judgment of ovarian malignanay degree and disease progression.(3) The joint detection of GILZ and Ki-67 can help judge clinical diagnosis, treatment and prognosis in cancer patients.